TrialClinical drug investigation2014

A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial.

Daniela Baldoni et al.PubMed ↗Publisher ↗

No numbers read from the abstract.